As of Nov 2, 2026: Yu Xia (Director, SMMT) reported no shares bought or sold themselves in the last 12 months (Form 4). SMMT's Quality Score is -4. Scores as of 10:25 PM ET, 15 minutes behind.

Yu Xia

Director of Summit Therapeutics

No Form 4 from Yu Xia in the last 12 months. The last one we read was dated Oct 21, 2025.

Bought$012 months Sold$012 months Last filedOct 21, 2025a Form 4

From SEC Form 4s · Insiders have 2 business days to file a trade

Every trade Yu Xia reported

None in the last 12 months, as filed.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See SMMT's 14 chart checksSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Yu Xia's companies

Where they file, with the stock's Quality Score

Company	Title, as filed	Trades	Quality Score
SMMTSummit TherapeuticsDirector	Directorfiled Oct 21, 2025	0	-4

Alerts for Yu Xia

One alert for each Form 4 they file.

Set an alert

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Use this page

Kept by Andrew Gomes, Breakaway's founder, from the SEC's Form 4 filings. Updated Oct 21, 2025.

Free to reuse with a link to this page.

How to cite

Breakaway, Yu Xia: Director at Summit Therapeutics (SMMT), Oct 21, 2025, getbreakaway.com/insiders/yu-xia

Journalists: email support@getbreakaway.com for the data behind this page.

Others who file at Summit Therapeutics

Insider trades by person